United States · FDA National Drug Code directory
Flucelvax
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 70461-656_507ef735-5913-4f01-831b-c53285db8f64
- Product NDC
- 70461-656
- Form
- INJECTION, SUSPENSION
- Composition / generic term
- INFLUENZA A VIRUS A/Tasmania/318/2025 CVR-351 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA A VIRUS A/Tasmania/787/2025 CVR-388 (H3N2) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA B VIRUS B/Arizona/21/2025 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED)
- Labeler
- Seqirus Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20260701 / 20270731
Source-listed ingredients
- INFLUENZA A VIRUS A/TASMANIA/318/2025 CVR-351 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) — 15 ug/.5mL
- INFLUENZA A VIRUS A/TASMANIA/787/2025 CVR-388 (H3N2) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) — 15 ug/.5mL
- INFLUENZA B VIRUS - B/ARIZONA/21/2025 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) — 15 ug/.5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 10 SYRINGE, GLASS in 1 CARTON (70461-656-03) / .5 mL in 1 SYRINGE, GLASS (70461-656-04) · 70461-656-03
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →